Cencora, Inc. $COR Shares Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 6.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,209 shares of the company’s stock after purchasing an additional 2,586 shares during the period. Cencora comprises approximately 0.8% of Knights of Columbus Asset Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. Knights of Columbus Asset Advisors LLC’s holdings in Cencora were worth $13,256,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Voleon Capital Management LP acquired a new position in shares of Cencora in the 1st quarter valued at about $3,111,000. Exchange Traded Concepts LLC raised its position in Cencora by 4.5% during the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock valued at $307,000 after acquiring an additional 48 shares in the last quarter. Focus Partners Wealth lifted its holdings in Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after acquiring an additional 1,171 shares during the period. Fiduciary Alliance LLC purchased a new stake in Cencora in the 2nd quarter worth approximately $262,000. Finally, Martin Capital Partners LLC grew its stake in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a report on Saturday, September 27th. Jefferies Financial Group increased their target price on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company lifted their price target on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $311.25.

Cencora Stock Down 2.0%

Shares of NYSE COR opened at $302.54 on Monday. The firm has a market cap of $58.66 billion, a price-to-earnings ratio of 31.13, a price-to-earnings-growth ratio of 1.41 and a beta of 0.63. The company’s 50-day simple moving average is $294.68 and its 200-day simple moving average is $290.41. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $315.23.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. Equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is currently 22.63%.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares in the company, valued at $11,389,460. The trade was a 11.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,993 shares of company stock worth $16,292,923 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.